Xintela initiates a study on the treatment of cartilage damage in horses in the USA.

Xintela initiates a study on the treatment of cartilage damage in horses in the USA.

Xintela AB (publ) announces today that the company have initiated a study, in the USA, on the treatment of cartilage damage in horses. The study is being conducted in collaboration with an eminent research group at Cornell Univesity. Xintela's stem cells have been injected into horse joints and the study is expected to be completed by the end of the year. The purpose of the study is, in part, to determine that stem cells are safe to use and, in part, to examine if they can improve joint function.

Read in PDF

– We are very happy that the study has started and we are excitedly awaiting the results, which are expected at the end of the year. We are also excited that we have now initiated a collaboration with a research group at Cornell University who are renowned in the field of veterinary medicine and orthopaedic diseases, with a special focus in, amongst others, regenerative medicine, says Evy Lundgren-Åkerlund, CEO at Xintela.  

Xintela's marker technology has been used to isolate so-called mesenchymal stem cells from adipose tissue from a horse donor and to select the correct type of stem cells to use in the horse study. Xintela's laboratory research has shown that those stem cells, which the company's patented markers select, have the ability to develop into cartilage-producing cells.  At the end of March, Xintela sent the stem cells to Cornell University and the first stem cells have now been injected into horse joints, with damaged cartilage.  

The goal of the study is primarily to determine if Xintela's stem cells are safe to use and are tolerated well by the horse under treatment.  The study will also examine if stem cells have the ability to improve joint function, determined by examining lameness (a sign of pain) and regeneration of cartilage tissue.  

– The results of the study are important in our continued ambition to develop a stem cell product for horses but also to prepare for clinical studies in man, since the horse is an excellent animal model for human conditions, says Evy Lundgren-Åkerlund.

About the study

The study, which is being conducted in collaboration with Cornell University, comprises eight horses.  Horses, with damaged cartilage in joints, that are equivalent to the ankles in humans, have stem cells injected into one joint and a saline solution into the other joint.  During the study, any possible reaction to the stem cells will be investigated, as will the effect of the stem cells on lameness and joint mobility as a measure of joint function. Multiple analyses of joint fluid, cells and tissues will also be conducted. The study is expected to be completed by the end of the year.

About Xintela

Xintela AB (publ) is a Swedish biomedical company active in the fields of regenerative medicine and cancer, with a focus on cartilage damage and brain tumours.  The Company was founded in 2009, but research and development started in 2013. The key to Xintela's business is the Company's patented marker technology, XINMARK™. Xintela's markers are specific proteins which sit as "recognition flags" on certain cell surfaces.  The markers make it possible to identify and quality assure cartilage cells and stem cells and also to select a certain type of stem cells which can develop into cartilage cells. Through this technology, Xintela can, in a unique way, quality assure stem cells for the repair of damaged cartilage. The XINMARK™-technology makes it also possible to direct antibody treatment to cells in glioblastoma brain tumours with the goal to slow down tumour growth. Xintela is listed on Nasdaq First North since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Consensus Asset Management AB.  

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO

Tel: +46-70-329 18 71


Medicon Village

223 81 Lund, Sweden  

Any questions on trade in Xintela's shares and options will be answered by the Company's Certified Adviser, Consensus Asset Management AB. Telephone: +46-31-745 50 00.

Media and Investor Relations related questions should be directed to:

Adam Lindblom, Laika Consulting

Tel: +46 -73-062 20 13



Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.

December 29, 2017
Xintela licenses human antibody technology for cancer therapy
December 19, 2017
Xintela to collaborate with Japanese CellSeed Inc.
November 13, 2017
Xintela raises 17 million SEK in debt and equity
October 17, 2017
Keld Søndergaard has resigned from the company’s Board of Directors, citing personal reasons.
September 11, 2017
Xintela building own GMP-facility for stem cell production
July 17, 2017
Xintela recruits Liselotte Theorell as Director Product Development and Quality Management
June 22, 2017
Xintela participates in multi-million, government funded initiative to form a cell and gene therapy research center
May 22, 2017
Xintela signs Memorandum of Understanding with the leading European cell therapy company, CO.DON
May 9, 2017
Xintela: Keld Sondergaard nominated as new board member
March 21, 2017
Xintela announces today that Thomas Areschoug has been recruited to the business development team......
February 8, 2017
(In Swedish) Xintela: Insynspersoner och huvudägare avser nyttja teckningsoptioner av serie TO1
January 20, 2017
Xintela reports positive preclinical results in cancer project
January 4, 2017
Xintela´s stem cells show positive treatment effects on cartilage damage in horse study
December 22, 2016
Xintela reports positive results from completed horse study
September 12, 2016
Xintela announces that Rickard Mosell has been recruited as Head of Business Development from October 1, 2016.
August 22, 2016
Xintela today announces that it has settled a dispute and will receive 1,500,000 Swedish Crowns in compensation.
June 23, 2016
Xintela announces that Christer Betsholtz has been engaged as a scientific and strategic advisor
June 1, 2016
Xintela strengthens its organisation wih the appointment of Caroline Ehrencrona as Director Clincial Development and Regulatory Affairs
April 25, 2016
Xintela initiates a study on the treatment of cartilage damage in horses in the USA.
March 16, 2016
Xintela's press releases are currently only published in Swedish. Please contact us if you have further questions.
January 5, 2018
Pre-Christmas breakthrough promises an exciting 2018
September 28, 2017
‍Strategic decisions that builds significant value
July 19, 2017
Focusing on Stem Cell Production and Preparations for Clinical Trials
May 16, 2017
On the 21st March 2017, Xintela reported that it was strengthening its Business Development team...
April 5, 2017
A word from the CEO
April 5, 2017
The subscription period for shares supported by warrants has started
December 29, 2016
A Year of Significant Progress
December 14, 2016
Glioblastoma—Xintela's Focus in the Cancer Arena
November 8, 2016
Starting the Autumn with an increased focus on Xintela’s commercial development
October 19, 2016
Since our listing in the Spring, the company has developed in a very positive way and we are on track with the milestones we have set.
August 11, 2016
Confidence in the future with a strong organisation
August 11, 2016
Welcome to Xintela's newsletter
February 22, 2018
Year-End Report 2017
February 9, 2017

Dr. Marcus Keep comments on Xintelas glioblastoma project.

January 31, 2017

Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.

January 30, 2017

Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.

December 28, 2016

In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.

December 13, 2016

See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.

March 24, 2016

See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).

March 22, 2016

See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.

March 16, 2016

Investor presentation from Lund - Jan 27

March 15, 2016

Interview with Xintelas CEO

March 23, 2016
(Article in Swedish) Xintela tar behandling av ledskador och cancer till First North.
March 23, 2016
(Article in Swedish) Grundare av Xintela ser notering som viktig milstolpe
March 23, 2016
(Article in Swedish) Xintela covered in Life Science Sweden
February 24, 2016
(Article in Swedish) Rapidus: Xintela på väg till First North
March 17, 2016
Future financial analyses of Xintela will be published here.